Moreover, immunoblotting analysis of the p53 signaling pathway proved that PMIBcr/Abl‐R6 efficiently activated the p53 pathway in this imatinib‐resistant ALL cell line (Figure 5B). The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.